Inhibition of bacterial efflux pumps: a new strategy to combat increasing antimicrobial agent resistance

Bibliography

• LOMOVSKAYA O, WARREN MS, LEE A et al.: Identification and characterization of inhibitors of multi-drug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob. Agents Chemother. (2001) 45:105–116.
   PubMed Web of Science ®Google Scholar
• •Describes the approach employed for the discovery of RND efflux pump inhibitors and the initial characterisation of lead compounds.
   Google Scholar
• RYAN BM, DOUGHERTY TJ, BELIEAU D, CHANG J, DOUGHERTY BA, BARRETT JF: Efflux in bacteria: what do we really know about it? Expert Opin. Investig. Drugs(2001) 10: 1409–1422.
   Google Scholar
• •A good general review, including a description of past and current work on efflux pump inhibitors.
   Google Scholar
• VAN BAMBEKE F, BALZI E, TULKENS PM: Antibiotic efflux pumps. Biochem. Pharmacol (2000) 60:457–470.
   PubMed Web of Science ®Google Scholar
• ••An excellent review of antimicrobial agentefflux pumps.
   Google Scholar
• PUTMAN M, VAN VEEN HW, KONINGS WN. Molecular properties of bacterial multi-drug transporters. Microbiol Ma Biol. Rev (2000) 64:672–693.
   PubMed Web of Science ®Google Scholar
• LOMOVSKAYA O, WATKINS WJ: Efflux pumps: their role in antibacterial drug discovery. Curl: Med. Chem. (2001) 8:1699–1711.
   PubMed Web of Science ®Google Scholar
• VAN VEEN HW, VENEMA K, BOLHUIS H et al: Drug transport mediated by a bacterial homologue of the human multi-drug transporter MDR1. Proc. Natl. Acad. Sci. USA (1996) 93:10668–10672.
   PubMed Web of Science ®Google Scholar
• ROSS JI, EADY EA, COVE JH, CUNLIFFE WJ, BAUMBERG S, WOOTON JC: Inducible erythromycin resistance in staphylococci is encoded by a member of the ATP-binding transport super-gene family. Ma Microbiol (1990) 4:1207–1214.
   PubMed Web of Science ®Google Scholar
• MORITA Y, KODAMA K, SHIOTA S et al.: NorM, a putative multi-drug efflux protein, of Vibrio parahaemolyticus and its homologue in Escherichia coil. Antimicrob. Agents Chemother. (1998) 42:1778–1782.
   Google Scholar
• MIYAMAE S, UEDA O, YOSHIMURA F, HWANG J, TANAKA Y, NIKAIDO H: A MATE family multi-drug efflux transporter pumps out fluoroquinolones in Bacteroides thetaiotarnicron. Antimicrob. Agents Chemother: (2001) 45:3341–3346.
   Google Scholar
• UBUKATA K, ITOH-YAMASHITA N, KONNO M: Cloning and expression of the norA gene for fluoroquinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. (1989) 33:1535–1539.
   PubMed Web of Science ®Google Scholar
• •The first description of NorA.
   Google Scholar
• NEYFAKH AA, BIDNENKO VE, CHEN LB: Efflux-mediated multi-drug resistance in Bacillus subtilic similarities and dissimilarities with the mammalian system. Proc. Natl. Acad. Sci. USA (1991) 88:4781–4785.
   PubMed Web of Science ®Google Scholar
• •The first description of Bmr.
   Google Scholar
• BOLHUIS H, POELARENDS G, VAN VEEN HW, POOLMAN B, DRIESSEN AJ, KONINGS WN: The lactococcal ImrP gene encodes a proton-motive force-dependent drug transporter. J. Biol. Chem. (1995) 270:26092–26098.
   PubMed Web of Science ®Google Scholar
• NIKAIDO H, ZGURSKAYA HI: AcrAB and related multi-drug efflux pumps of Escherichia coil MoL Microbiol Biotechnol (2001) 3:215–218.
   Google Scholar
• POOLE K: multi-drug efflux pumps andantimicrobial resistance in Pseudomonas aeruginosa and related organisms. MoL MicrobioL Biotechnol (2001) 3:255–264.
   PubMed Web of Science ®Google Scholar
• POOLE K, SRIKUMAR R: multi-drug efflux in Pseudomonas aeruginosa: components, mechanisms and clinical significance. Curr. Top. Med. Chem. (2001) 1:59–71.
   PubMedGoogle Scholar
• ••An excellent review of the P aeruginosaRND drug pumps.
   Google Scholar
• LITTLEJOHN TG, DIBERARDINO D, MESSEROTTI LJ, SPIERS SJ, SKURRAY RA: Structure and evolution of a family of genes encoding antiseptic and disinfectant resistance in Staphylococcus aureus. Gene (1991) 101:59–66.
   PubMed Web of Science ®Google Scholar
• ARKIN IT, RUSS WP, LEBENDIKER M, SCHULDINER S: Determining the secondary structure and orientation of EmrE, a multi-drug transporter, indicates a transmembrane four-helix bundle. Biochemistry (1996) 35:7233–7238.
   PubMed Web of Science ®Google Scholar
• VAN VEEN HW, MARGOLLES A, MULLER M, HIGGINS CE KONINGS WN: The homodimeric ATP-binding cassette transporter LmrA mediates multi-drug transport by an alternating two-site (two-cylinder engine) mechanism. EMBO (2000) 19:2503–2514.
   PubMed Web of Science ®Google Scholar
• BIBI E, EDGAR R: A single membrane-embedded negative charge is critical for recognizing positively charged drugs by the Escherichia coli multi-drug resistance protein MdfA. EMBO J. (1999) 18:822–832.
   PubMed Web of Science ®Google Scholar
• YERUSHALMI H, SCHULDINER S: A model for coupling H+ and substrate fluxes based on 'time-sharing' of a common binding site. Biochemistry (2000) 39:14711–14719.
   PubMed Web of Science ®Google Scholar
• BLACKMORE CG, McNAUGHTON PA, VAN VEEN HW: Multi-drug transporters in prokaryotic and eukaryotic cells: physiological functions and transport mechanisms. Ma Membr: Biol. (2001) 18:97–103.
   PubMed Web of Science ®Google Scholar
• NEYFAKH AA: Mystery of multi-drug transporters: the answer can be simple. Ma Microbia 44:1123-1130.
   Google Scholar
• MARKHAM PN, NEYFAKH, AA: Inhibition of the multi-drug transporter NorA prevents emergence of norfloxacin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother: (1996) 40:2673–2674.
   PubMed Web of Science ®Google Scholar
• MARKHAM PN: Inhibition of the emergence of ciprofloxacin resistance in Streptococcus pneumoniae by the multi-drug efflux inhibitor reserpine. Antimicrob. Agents Chemother. (1999) 43:988–989.
   PubMed Web of Science ®Google Scholar
• NIKAIDO H: Multi-drug efflux pumps of Gram-negative bacteria.' Bacteria (1996) 178:5853–5859.
   PubMed Web of Science ®Google Scholar
• POOLE K: Efflux-mediated resistance to fluoroquinolones in Gram-negative bacteria. Antimicrob. Agents Chemother: (2000) 44:2233–2241.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI N, NISHINO K, YAMAGUCHI A: Novel macrolide-specific ABC-type transporter in Escherichia coll. Bacteria (2001) 183:5639–5644.
   PubMed Web of Science ®Google Scholar
• MCMURRY L, PETRUCCI RE, LEVY SB: Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coll. Proc. Nati Acad. Sci. USA (1980) 77:3974–3977.
   PubMed Web of Science ®Google Scholar
• •The original description of efflux-related resistance to tetracycline.
   Google Scholar
• NIKAIDO H: Multiple antibiotic resistance and efflux. Carr: Opin. Microbia (1998) 1:516–523.
   PubMed Web of Science ®Google Scholar
• NIKAIDO H: Preventing drug access to targets: cell surface permeability barriers and active efflux in bacteria. Semin. Cell Dev. Biol. (2001) 12:215–223.
   PubMed Web of Science ®Google Scholar
• TAYLOR DE, CHAU A: Tetracycline resistance mediated by ribosomal protection. Antimicrob. Agents Chemother: (1996) 40:1–5.
   PubMed Web of Science ®Google Scholar
• SPEER BS, SALYERS AA. Novel tetracycline resistance gene that chemically modifies tetracycline.' Bacteria (1989) 171:48–53.
   Google Scholar
• CHOPRA I, ROBERTS M: Tetracycline antibiotics: mode of action, applications, molecular biology and epidemiology of bacterial resistance. Microbia Ma Biol. Rev (2001) 65:232–260.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review of tetracyclineantibiotics.
   Google Scholar
• NELSON ML, PARK BH, ANDREWS JS, GEORGIAN VA, THOMAS RC, LEVY SB: Inhibition of the tetracycline efflux antiport protein by 13-thio-substituted 5-hydroxy-6-deoxytetracyclines..I. Med. Chem. (1993) 36:370–377.
   Web of Science ®Google Scholar
• NELSON ML, PARK BH, LEVY SB: Molecular requirements for the inhibition of the tetracycline antiport protein and the effect of potent inhibitors on the growth of tetracycline-resistant bacteria. Med. Chem. (1994) 37:1355–1361.
   Web of Science ®Google Scholar
• NELSON ML, LEVY SB: Reversal of tetracycline resistance mediated by different bacterial tetracycline resistance determinants by an inhibitor of the Tet(B) antiport protein. Antimicrob. Agents Chemother. (1999) 43:1719–1724.
   PubMed Web of Science ®Google Scholar
• HIRATA T, WAKATABE R, NIELSEN J et A novel compound, 1,1-dimethy1-5-(1-hydroxypropyl)-4,6,7-trimethylindan, is an effective inhibitor of the tet(K) geneencoded metal-tetracycline/H+ antiporter of Staphylococcus aureus. FEBS Lett. (1997)412:337–340.
   PubMed Web of Science ®Google Scholar
• SILVIA AM, GAVITT NE, PERE WD, HAYASHI SF: Identification of a tetracycline efflux resistance reverser UK-57,562. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. (1999).
   Google Scholar
• ROTHSTEIN DM, MCGLYNN M, BERNAN V et al.: Detection of tetracyclines and efflux pump inhibitors. Antimicrob. Agents Chemother. (1993) 37:1624–1629.
   PubMed Web of Science ®Google Scholar
• YOSHIDA T, MURATANI T, IYOBE S, MITSUHASHI S: Mechanisms of high-level resistance to fluoroquinolones in urinary 38:1466-1469.
   Google Scholar
• CHEN HY, YUAN M, LIVERMORE DM: Mechanisms of resistance to beta-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993. J. Med. Microbia (1995) 43:300–309.
   PubMed Web of Science ®Google Scholar
• FUKUDA H, HOSAKA M, IYOBE S, GOTOH T, NISHINO T, HIRAI K: nfvC-type quinolone resistance in a clinical isolate of Pseudomonas aeruginosa. Antimicrob. Agents Chemother: (1995) 39:790–792.
   Google Scholar
• LOMOVSKAYA O, LEE A, HOSHINO K et al.: Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. (1999) 43:1340–1346.
   Google Scholar
• •Describes methodology employed to create Mex pump-deficient strains.
   Google Scholar
• LEE MD, GALAZZO JL, STALEY AL et al.: Microbial fermentation-derived inhibitors of efflux-pump-mediated drug resistance. II Farmaco (2001) 56:81–85.
   PubMedGoogle Scholar
• RENAU TE, LEGER R, FLAMME EM et al.: Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin. Med. Chem. (1999) 42:4928–4931.
   Web of Science ®Google Scholar
• RIBERA A, RUIZ J, JIMENEZ DE ANTAMT, VILA J: Effect of an efflux pump inhibitor on the MIC of nalidixic acid for Acinetobacter baumanii and Stenotrophomonas maltophilia clinical isolates.' Antimicrob. Chemother. (2002) 49:697–702.
   PubMed Web of Science ®Google Scholar
• WARREN MS, LEE JC, LEE A, HOSHINO K, ISHIDA H, LOMOVSKAYA 0. An inhibitor of the Mex pumps from Pseudomonas aeruginosa is also a substrate of these pumps. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (2000).
   Google Scholar
• RENAU TE, LEGER R, FLAMME EM et al.: Addressing the stability of C-capped dipeptide efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa. Bioorg. Med. Chem. Lett. (2001) 11:663–667.
   Web of Science ®Google Scholar
• RENAU TE, LEGER R, YEN R et al: Peptidomimetics of efflux pump inhibitors potentiate the activity of levofloxacin in Pseudomonas aeruginosa. Biorg. Med. Chem. Lett. (2002) 12:763–766.
   Web of Science ®Google Scholar
• GRIFFITH D, LOMOVSKAYA O, LEE VJ, DUDLEY M: Potentiation of levofloxacin by MC-02,595, a broad spectrum efflux pump inhibitor in mouse models of infection due to Pseudomonas aeruginosa with combinations of different Mex pump expression and a gyrA mutation. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (2000).
   Google Scholar
• CHO D, LOFLAND D, BLAIS K et al.: Anefflux pump inhibitor, MC-04,124, enhances the activity of macrolides against Gram-negative bacteria. 40th Literscience Conference on Antimicrobial Agents and Chemotherapy (2000).
   Google Scholar
• GRIFFITH D, CORCORAN E, SORENSEN K, CHO D, LOMOVSKAYA O, DUDLEY MN. Potentiation of levofloxacin and azithromycin by MC-04,124, a broad spectrum efflux pump inhibitor, in mouse models of infection due to strains of I? aeruginosa and E. coil expressing efflux pumps. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (2001).
   Google Scholar
• RENAU TE, LEGER R, FILONOVA L et al.: Conformationally restricted analogs of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (2001).
   Google Scholar
• ZHANG JZ, WATKINS WJ, LEE VJ et al.: 2-(aminoalkyl)benzimidazoles - a class of broad spectrum efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aemginosa. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (2001).
   Google Scholar
• LEE JC, GALAZZO JL, IANIRO T et al.: MF-EA-371a and ME-EA-3718, novel bacterial efflux pump inhibitors from microbial fermentation. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (2000).
   Google Scholar
• CHEVALIER J, ATIFI S, EYRAUD A, MAHAMOUD A, BARBE J, PAGES J-M: New pyridoquinoline derivatives as potential inhibitors of the fluoroquinolone efflux pump in resistant Enterobacter aerogenes strains.j Med. Chem. (2001) 44:4023–4026.
   Google Scholar
• PAULSEN IT, BROWN MH, SKURRAY RA: Proton-dependent multi-drug efflux systems. Microbial. Rev (1996) 60:575–608.
   PubMedGoogle Scholar
• ••A comprehensive review of phylogeny andknown structure and function data.
   Google Scholar
• NG EYW, TRUCKSIS M, HOOPER DC:Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome. Antimicrob. Agents Chemother (1994) 38:1345–1355.
   PubMed Web of Science ®Google Scholar
• AESCHLIMANN JR, DRESSER LD, KAATZ GW, RYBAK MJ: Effects of NorA inhibitors on M vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin and norfloxacin in genetically related strains of Staphylococcus aureus. Antimicrob. Agents Chemother (1999) 43:335–340.
   PubMed Web of Science ®Google Scholar
• AESCHLIMANN JR, KAATZ GW, RYBAK MJ: The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureusin an in-vitro infection model. Antimicrob. Chemother. (1999) 44:343–349.
   Web of Science ®Google Scholar
• ZAMORA JM, PEARCE HL, BECK WT: Physical-chemical properties shared by compounds that modulate multi-drug resistance in human leukemic cells. Ma Pharmacol (1988) 33:454–462.
   PubMed Web of Science ®Google Scholar
• AHMED M, BORSCH CM, NEYFAKH AA, SCHULDINER S: Mutants of the Bacillus subtilis multi-drug transporter Bmr with altered sensitivity to the antihypertensive alkaloid reserpine. " Biol. Chem. (1993) 268:11086–11089.
   PubMed Web of Science ®Google Scholar
• MARKHAM PN, WESTHAUS E, KLYATCHKO K, JOHNSON ME, NEYFAKH AA: Multiple novel inhibitors of the NorA multi-drug transporter of Staphylococcus aureus. Antimicrob. Agents Chemother. (1999) 43:2404–2408.
   PubMed Web of Science ®Google Scholar
• •Describes the approach employed for the discovery and initial evaluation of inhibitors of the S. aureusNorA multi-drug efflux pump.
   Google Scholar
• STERMITZ FR, LORENZ P, TAWARA JN, ZENEWICZ LA, LEWIS K: Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5'-methoxyhydnocarpin, a multi-drug pump inhibitor. Proc. Natl. Acad. Sci. USA (2000) 97:1433–1437.
   PubMed Web of Science ®Google Scholar
• GUZ NR, STERMITZ FR: Synthesis and structures of regioisomeric hydnocarpin-type flavonolignans. Nat. Prod. (2000) 63:1140–1145.
   PubMed Web of Science ®Google Scholar
• GUZ NR, STERMITZ FR, JOHNSON JB et al: Flavonolignan and flavone inhibitors of a Staphylococcus aureus multi-drug resistance pump: structure-activity relationships. Med. Chem. (2001) 44:261–268.
   Web of Science ®Google Scholar
• HYAFIL F, VERGELY C, DU VIGNAUD P, GRAND-PERRET T: In vitro and M vivo reversal of multi-drug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. (1993) 53:4595–4602.
   PubMed Web of Science ®Google Scholar
• KRISTIANSEN JE: The antimicrobial activity of psychotherapeutic drugs and stereo-isomeric analogues. Dan. Med. Bull. (1990) 37:165–182.
   PubMed Web of Science ®Google Scholar
• KRISTIANSEN JE: Chlorpromazine: nonantibiotics with antimicrobial activity - new insights in managing resistance? Carr. Opin. Invest. Drugs (1993) 2:587–591.
   Google Scholar
• KRISTIANSEN JE, AMARAL L: The potential management of resistant infections with nonantibiotics." Antimicrob. Chemother. (1997) 40:319–327.
   PubMed Web of Science ®Google Scholar
• SRIDHAR KS, KRISHNAN A, SAMY TS et al.: Prochlorperazine as a doxorubicin-efflux blocker: Phase I clinical and pharmacokinetic studies. Cancer Chemother. Pharmacol (1993) 31:423–430.
   PubMed Web of Science ®Google Scholar
• SRIDHAR KS, KRISHNAN A, SAMY TS et al: Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker. Cancer Chemother. Pharmacol (1994) 34:377–384.
   PubMed Web of Science ®Google Scholar